Literature DB >> 1497555

Recently characterised autoantibodies and their clinical significance.

A Sturgess1.   

Abstract

Multisystem autoimmune diseases such as systemic lupus erythematosus (SLE), primary Sjögren's syndrome (SS), scleroderma and polymyositis are characterised by the presence of antinuclear antibodies (ANAs). Immunoblotting and cDNA cloning studies reveal that the autoantigens of the multisystem autoimmune diseases are important proteins involved in nucleic acid metabolism, including tRNA charging, intron splicing, DNA uncoiling, and RNA polymerase co-factors. Each specific syndrome associates with a restricted variety of ANAs, e.g. anti-La with primary SS, anti-Sm with SLE, anti-synthetase enzymes with myositis, anti-topoisomerase 1 (Scl 70) with scleroderma, and anti-centromere with CREST. Precise characterisation of an ANA provides valuable diagnostic and prognostic information, and should be performed when an ANA is detected.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1497555     DOI: 10.1111/j.1445-5994.1992.tb02126.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  3 in total

1.  Autoantibodies to evolutionarily conserved epitopes of enolase in a patient with discoid lupus erythematosus.

Authors:  V M Gitlits; J W Sentry; M L Matthew; A I Smith; B H Toh
Journal:  Immunology       Date:  1997-11       Impact factor: 7.397

2.  Focal sialadenitis in patients with ankylosing spondylitis and spondyloarthropathy: a comparison with patients with rheumatoid arthritis or mixed connective tissue disease.

Authors:  L M Helenius; J H Hietanen; I Helenius; H Kautiainen; H Piirainen; L Paimela; M Lappalainen; R Suuronen; C Lindqvist; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2001-08       Impact factor: 19.103

3.  Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis.

Authors:  A J Czaja; F Cassani; M Cataleta; P Valentini; F B Bianchi
Journal:  Dig Dis Sci       Date:  1997-08       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.